豐原藥業(000153.SZ):淮南泰複製藥以自籌資金3000萬元對郎利生物增資
格隆匯 11 月 20日丨豐原藥業(000153.SZ)公佈,2020年11月19日,公司召開第八屆十次董事會,以9票同意、無反對和棄權票,審議通過《關於全資子公司淮南泰複製藥有限公司對其子公司增資的議案》。公司董事會同意淮南泰複製藥有限公司與安徽東庚生物科技有限公司、安徽雪郎生物科技股份有限公司簽訂《安徽郎利生物化工有限公司增資擴股的協議》。協議約定:郎利生物增資擴股註冊資本由人民幣6000萬元增至1億元。其中,淮南泰複製藥有限公司以自籌資金3000萬元對郎利生物增資,佔郎利生物增資後總股本的51%。
此次對外投資是在充分發揮投資各方的資金和技術優勢的基礎上,擴大郎利生物原料藥的研發和生產規模,以進一步拓展公司醫藥產業鏈的外延式發展,提升公司的綜合實力和盈利水平。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.